BILIX Co.
Latest round
- Series B
Last raised
- Apr 2026
Total raised
- $20M
Investors
- 12
About BILIX Co.
, Ltd. focuses on advancing therapeutic solutions through its proprietary technologies. Myung-lip Kim, who has a history of founding innovative biotech ventures, serves as both CEO and founder., Ltd. BILIX specializes in developing innovative therapeutic solutions based on its proprietary PEGylated bilirubin platform technology, known as Brixelle®. This flagship product utilizes the antioxidant properties of bilirubin combined with polyethylene glycol (PEG) to create novel treatments for oxidative stress and inflammation. Brixelle® is formulated into a nanoparticle delivery system for applications in treating intractable inflammatory diseases and enhancing anti-cancer drug delivery. The technology has attracted interest from pharmaceutical partners and research institutions in Asia, Europe, and North America, aiming to serve healthcare providers and research organizations. BILIX's revenue model is primarily based on partnerships and collaborations with research organizations and healthcare institutions. The company engages in joint research and development efforts which might include licensing agreements and co-development contracts for its products. The Brixelle® platform may be provided to clinical partners in exchange for milestone payments and royalties on future sales. As the company approaches commercialization, revenue generation is anticipated from both B2B transactions with pharmaceutical firms and potential direct-to-consumer applications once products are launched. The company is targeting expansion into key markets across Asia, Europe, and North America, with a timeline for market entry contingent on the successful completion of ongoing research and product development initiatives.
Who invested in BILIX Co.
12 investors across 2 rounds
See all investors in BILIX Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about BILIX Co.
Who invested in BILIX Co.?
BILIX Co. has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BILIX Co. raised?
BILIX Co. has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did BILIX Co. last raise money?
BILIX Co.'s most recent round on record is a Series B, in Apr 2026.
What does BILIX Co. do?
BILIX Co. is a biotechnology company.
Where is BILIX Co. headquartered?
BILIX Co. is headquartered in Yongin, South Korea.
Which VCs invest in companies like BILIX Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at BILIX Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like BILIX Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.